Fast Five Quiz: Tardive Dyskinesia Management

Christoph U. Correll, MD

Disclosures

February 22, 2021

The US Food and Drug Administration (FDA) has approved two VMAT2 inhibitors for the treatment of adults with TD: valbenazine and deutetrabenazine. These drugs modulate the presynaptic packaging and release of dopamine into the synapse and may offset the movement-related effects of antipsychotics and other dopaminergic blockers.

Atypical antipsychotics may be used instead of typical antipsychotics to control psychosis, in order to reduce the risk for TD. Whereas typical antipsychotics primarily block dopamine D2 receptors, atypical antipsychotics bind variably to dopaminergic, serotonergic, alpha-adrenergic, histaminic, and muscarinic receptors. In particular, a switch to clozapine has been recommended as treatment for patients with TD who require antipsychotics. Clozapine is one of the most effective atypical antipsychotic for treatment-refractory schizophrenia, but it also has other adverse effects that require monitoring. Although clozapine has been associated with TD, the incidence of TD with clozapine and other atypical antipsychotics appears markedly lower compared with typical antipsychotics.

There has been anecdotal and inconsistent evidence that vitamin E (not vitamin D) has helped some individuals with TD.

Learn more about the workup of TD.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....